Egashira Nobuaki, Okuno Ryoko, Matsushita Michihiko, Abe Moe, Mishima Kenichi, Iwasaki Katsunori, Nishimura Ryoji, Oishi Ryozo, Fujiwara Michihiro
Department of Neuropharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka 814-0180, Japan.
Eur J Pharmacol. 2008 Sep 11;592(1-3):103-8. doi: 10.1016/j.ejphar.2008.06.100. Epub 2008 Jul 4.
Aripiprazole is a first next-generation atypical antipsychotic drug with dopamine system stabilizing, serotonin (5-hydroxytryptamine, 5-HT) 5-HT1A receptor partial agonistic, and 5-HT2A receptor antagonistic properties. In the present study, we examined the effect of aripiprazole on marble-burying behavior, which has been considered an animal model of obsessive-compulsive disorder, and compared this with the effects of other atypical antipsychotics such as olanzapine and quetiapine. Aripiprazole (1 mg/kg, i.p.) inhibited marble-burying behavior without affecting the locomotor activity in mice. Conversely, olanzapine (3 mg/kg, i.p.) and quetiapine (100 mg/kg, p.o.) showed significant suppression of locomotor activity and impairment of motor coordination at the dose that inhibited marble-burying behavior. On the other hand, a selective 5-HT1A receptor antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl) cyclohexane (WAY100635, 3 mg/kg, i.p.) markedly antagonized the inhibition of marble-burying behavior by 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT, 3 mg/kg, i.p.), a selective 5-HT1A/7 receptor agonist. By contrast, WAY100635 at the same dose had no effect on the inhibition of marble-burying behavior by aripiprazole (1 mg/kg, i.p.). Quinpirole, a dopamine D2 receptor agonist, showed significant suppression of locomotor activity at the dose that inhibited marble-burying behavior. Conversely, L-741,626, a selective dopamine D2 receptor antagonist, at a dose of 10 mg/kg inhibited marble-burying behavior without affecting the locomotor activity. On the other hand, ketanserin, a 5-HT2A receptor antagonist, had no effect on the marble-burying behavior. These findings suggest that aripiprazole may be a useful drug for the treatment of obsessive-compulsive disorder, and that aripiprazole inhibits the marble-burying behavior via 5-HT1A receptor-independent mechanisms.
阿立哌唑是一种第一代的下一代非典型抗精神病药物,具有多巴胺系统稳定、5-羟色胺(5-羟色胺,5-HT)5-HT1A受体部分激动以及5-HT2A受体拮抗特性。在本研究中,我们检测了阿立哌唑对埋大理石行为的影响,埋大理石行为被认为是强迫症的一种动物模型,并将其与其他非典型抗精神病药物(如奥氮平和喹硫平)的作用进行了比较。阿立哌唑(1毫克/千克,腹腔注射)抑制了小鼠的埋大理石行为,而不影响其运动活性。相反,奥氮平(3毫克/千克,腹腔注射)和喹硫平(100毫克/千克,口服)在抑制埋大理石行为的剂量下,显著抑制了运动活性并损害了运动协调性。另一方面,选择性5-HT1A受体拮抗剂N-[2-[4-(2-甲氧基苯基)-1-哌嗪基]乙基]-N-(2-吡啶基)环己烷(WAY100635,3毫克/千克,腹腔注射)显著拮抗了选择性5-HT1A/7受体激动剂8-羟基-2-(二正丙基氨基)四氢萘(8-OH-DPAT,3毫克/千克,腹腔注射)对埋大理石行为的抑制作用。相比之下,相同剂量的WAY100635对阿立哌唑(1毫克/千克,腹腔注射)对埋大理石行为的抑制作用没有影响。喹吡罗,一种多巴胺D2受体激动剂,在抑制埋大理石行为的剂量下显著抑制了运动活性。相反,选择性多巴胺D2受体拮抗剂L-741,626,剂量为10毫克/千克时,抑制了埋大理石行为,而不影响运动活性。另一方面,5-HT2A受体拮抗剂酮色林对埋大理石行为没有影响。这些发现表明,阿立哌唑可能是一种治疗强迫症的有效药物,并且阿立哌唑通过不依赖5-HT1A受体的机制抑制埋大理石行为。